Company / EPS (Diluted)
Monopar Therapeutics EPS (Diluted) History
FY2017-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$0.35
FY2019
5-year range
-$1.89 / -$0.35
FY2017-FY2019
Trend
+81.5%
vs FY2018
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $-1.89 to $-0.35 over the past 2 years.
Based on SEC 10-K filings.
-0.35 in FY2019.
Improved from $-1.89 to $-0.35 over the past 2 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2019, eps (diluted) increased 81.5% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 19.82 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2019 | -$0.35 | +81.5% |
| FY2018 | -$1.89 | +0.0% |
| FY2017 | -$1.89 | - |
As of FY2019 · SEC 10-K · Updated Jun 28, 2026